NEMAURA
LIVE

Serial Number

79185414

Owner

Nemaura Pharma Limited

Attorney

Ali R. Latifi

Filing Date

Dec 24, 2015

Add to watchlist:

No watchlists yet
View on USPTO

NEMAURA Trademark

Serial Number: 79185414 • Registration: 5293350

NEMAURA is a trademark filed by Nemaura Pharma Limited on December 24, 2015. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Nemaura Pharma Limited (4 trademarks)

85 Toothill Road
Loughborough, Leiceste LE111PN , GB

Entity Type: 03

Trademark Details

Filing Date

December 24, 2015

Registration Date

September 26, 2017

Published for Opposition

July 11, 2017

Goods & Services

[ Pharmaceutical and veterinary preparations for treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Sanitary preparations for medical purposes; Diagnostic preparations and substances for medical or veterinary purposes; Medical diagnostic reagents; Antiserums for medical or veterinary diagnostic purposes; Vaccines for human beings and animals; Adjuvants for use with vaccines; Biological laboratory preparations for medical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Chemical preparations and reagents for medical, pharmaceutical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Viruses for the treatment of humans and animals for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Diagnostic preparations for medical purposes; In-vitro diagnostics for medical purposes; In-vivo diagnostics for medical purposes; Medical plasters; Transdermal patches for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal plasters for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal therapeutic drug delivery systems (TTS), namely, transdermal patches and plasters treated or impregnated with pharmaceutical active ingredients for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Medicated transdermal drug delivery patches featuring medication for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Vaccines; Drug delivery agents in the form of dissolvable films, coatings for tablets, capsules that facilitate the delivery of pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for injection in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Drug delivery agents in the form of liquid medications, tablets, powders, capsules, inhalants, nasal sprays, orally disintegrating tablets, and mouthwashes that facilitate the delivery of pharmaceutical preparations; Balms for medical purposes; Tonics for medical purposes, namely, for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Disinfectants, antiseptics ]

[ Surgical apparatus and instruments for medical, dental or veterinary use; Suture materials; Inhalers for medical purposes; Filters for inhalers for medical purposes; Inhalers for medical use; Inhalers for therapeutic use; Electromagnetic drug delivery apparatus for medical use; Drug delivery apparatus and devices, namely, medical apparatus and units for dosage, measuring and monitoring; Microneedle arrays for delivering medications; Hypodermic syringes for injections for medical purposes; Electrical drug delivery apparatus for medical use; Needles for medical and surgical use; Hypodermic needles ]

Medical research services; Conducting clinical trials for others; Medical research laboratory services; Medical research laboratory services for the analysis of samples taken from patients; Scientific analysis and research services, namely, DNA analysis services for scientific research purposes; Product development relating to pharmaceuticals, medicines, medicaments and veterinary products; Medical and health care testing services for research purposes, namely, clinical testing services, physician testing services for assisting pharmacists, pharmaceutical testing services, and medical laboratory and testing services; Pharmaceutical research and development services; Medical and scientific research information in the field of healthcare; Cosmetics research; Design and development of computer hardware and software and information storage retrieval services in the fields of diagnostic testing and preparations for the treatment, monitoring or diagnosis of disease

Filing History

PARTIAL INVALIDATION PROCESSED BY THE IB
Jun 6, 2025 INNP
NEW REPRESENTATIVE AT IB RECEIVED
Apr 24, 2025 NREP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Apr 11, 2025 INPS
INVALIDATION PROCESSED
Apr 11, 2025 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 23, 2025 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
May 23, 2024 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
May 23, 2024 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 20, 2024 APRE
TEAS SECTION 71 RECEIVED
Sep 26, 2023 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Sep 26, 2022 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 10, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 12, 2018 FICS
FINAL DISPOSITION PROCESSED
Jan 12, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 26, 2017 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 1, 2017 NREP
REGISTERED-PRINCIPAL REGISTER
Sep 26, 2017 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 15, 2017 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 30, 2017 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 30, 2017 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 11, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jul 11, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Jul 8, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 21, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 21, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 21, 2017 NONP
EXPARTE APPEAL TERMINATED
May 31, 2017 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
May 31, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
May 31, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 31, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
May 31, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 31, 2017 CNEA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
May 15, 2017 ERFR
EX PARTE APPEAL-INSTITUTED
May 15, 2017 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
May 15, 2017 JURT
EXPARTE APPEAL RECEIVED AT TTAB
May 15, 2017 EXAF
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 2, 2017 ADCH
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 14, 2016 GNFN
FINAL REFUSAL E-MAILED
Nov 14, 2016 GNFR
FINAL REFUSAL WRITTEN
Nov 14, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 21, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 21, 2016 TROA
REFUSAL PROCESSED BY IB
May 14, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 22, 2016 RFCS
REFUSAL PROCESSED BY MPU
Apr 22, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 22, 2016 RFCR
NON-FINAL ACTION WRITTEN
Apr 21, 2016 CNRT
ASSIGNED TO EXAMINER
Apr 11, 2016 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 5, 2016 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 1, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 31, 2016 REPR